Infliximab-induced remission improves physical activity in patients with active Crohn's disease
Autor(a) principal: | |
---|---|
Data de Publicação: | 2020 |
Outros Autores: | , , , , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Revista da Associação Médica Brasileira (Online) |
Texto Completo: | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0104-42302020001101566 |
Resumo: | SUMMARY AIM: To compare the level of physical activity (PA), exercise capacity, and body composition before and after infliximab-induced clinical remission in patients with Crohn's disease (CD). METHODS: This prospective longitudinal study evaluated 44 adult outpatients with active CD before infliximab administration and 24 weeks after infliximab therapy. The patients were evaluated for PA in daily life, exercise capacity, muscle strength, and body composition. RESULTS: 38 (86.4%) patients achieved infliximab-induced remission at 24 weeks and presented an increment in the number of steps taken of 1092 (7440±2980 vs. 6348±3177, respectively; p=0.006). The inactive time was reduced when compared to the baseline value (454.2±106.3 vs. 427.9±97.8, respectively; p=0.033). There was no difference in the distance walked before and after infliximab therapy, while there was an increase in the fat mass index in responders to infliximab compared to the baseline (19.1±7.6 vs. 14.9±5.8; p=0.001). CONCLUSIONS: Infliximab-induced remission was shown to be effective for increasing physical activity by improving the number of steps and reducing inactive time. The maintenance of clinical remission associated with incentives to regular PA may contribute to making these patients reach an ideal level of PA. |
id |
AMB-1_5c144a923b0dcf50ea76aef1f2b81fb1 |
---|---|
oai_identifier_str |
oai:scielo:S0104-42302020001101566 |
network_acronym_str |
AMB-1 |
network_name_str |
Revista da Associação Médica Brasileira (Online) |
repository_id_str |
|
spelling |
Infliximab-induced remission improves physical activity in patients with active Crohn's diseaseCrohn diseaseInflammatory Bowel DiseasesInfliximab. Motor activitySUMMARY AIM: To compare the level of physical activity (PA), exercise capacity, and body composition before and after infliximab-induced clinical remission in patients with Crohn's disease (CD). METHODS: This prospective longitudinal study evaluated 44 adult outpatients with active CD before infliximab administration and 24 weeks after infliximab therapy. The patients were evaluated for PA in daily life, exercise capacity, muscle strength, and body composition. RESULTS: 38 (86.4%) patients achieved infliximab-induced remission at 24 weeks and presented an increment in the number of steps taken of 1092 (7440±2980 vs. 6348±3177, respectively; p=0.006). The inactive time was reduced when compared to the baseline value (454.2±106.3 vs. 427.9±97.8, respectively; p=0.033). There was no difference in the distance walked before and after infliximab therapy, while there was an increase in the fat mass index in responders to infliximab compared to the baseline (19.1±7.6 vs. 14.9±5.8; p=0.001). CONCLUSIONS: Infliximab-induced remission was shown to be effective for increasing physical activity by improving the number of steps and reducing inactive time. The maintenance of clinical remission associated with incentives to regular PA may contribute to making these patients reach an ideal level of PA.Associação Médica Brasileira2020-11-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0104-42302020001101566Revista da Associação Médica Brasileira v.66 n.11 2020reponame:Revista da Associação Médica Brasileira (Online)instname:Associação Médica Brasileira (AMB)instacron:AMB10.1590/1806-9282.66.11.1566info:eu-repo/semantics/openAccessLucca,Fernando de AzevedoMalaguti,CarlaChebli,Liliana AndradeReboredo,Maycon MouraPinheiro,Bruno ValleRibeiro,Tarsila Campanha da RochaAzevedo,Felipe Meirelles deCorrêa,José Otávio do AmaralGaburri,Pedro DuarteChebli,Julio Maria Fonsecaeng2020-11-30T00:00:00Zoai:scielo:S0104-42302020001101566Revistahttps://ramb.amb.org.br/ultimas-edicoes/#https://old.scielo.br/oai/scielo-oai.php||ramb@amb.org.br1806-92820104-4230opendoar:2020-11-30T00:00Revista da Associação Médica Brasileira (Online) - Associação Médica Brasileira (AMB)false |
dc.title.none.fl_str_mv |
Infliximab-induced remission improves physical activity in patients with active Crohn's disease |
title |
Infliximab-induced remission improves physical activity in patients with active Crohn's disease |
spellingShingle |
Infliximab-induced remission improves physical activity in patients with active Crohn's disease Lucca,Fernando de Azevedo Crohn disease Inflammatory Bowel Diseases Infliximab. Motor activity |
title_short |
Infliximab-induced remission improves physical activity in patients with active Crohn's disease |
title_full |
Infliximab-induced remission improves physical activity in patients with active Crohn's disease |
title_fullStr |
Infliximab-induced remission improves physical activity in patients with active Crohn's disease |
title_full_unstemmed |
Infliximab-induced remission improves physical activity in patients with active Crohn's disease |
title_sort |
Infliximab-induced remission improves physical activity in patients with active Crohn's disease |
author |
Lucca,Fernando de Azevedo |
author_facet |
Lucca,Fernando de Azevedo Malaguti,Carla Chebli,Liliana Andrade Reboredo,Maycon Moura Pinheiro,Bruno Valle Ribeiro,Tarsila Campanha da Rocha Azevedo,Felipe Meirelles de Corrêa,José Otávio do Amaral Gaburri,Pedro Duarte Chebli,Julio Maria Fonseca |
author_role |
author |
author2 |
Malaguti,Carla Chebli,Liliana Andrade Reboredo,Maycon Moura Pinheiro,Bruno Valle Ribeiro,Tarsila Campanha da Rocha Azevedo,Felipe Meirelles de Corrêa,José Otávio do Amaral Gaburri,Pedro Duarte Chebli,Julio Maria Fonseca |
author2_role |
author author author author author author author author author |
dc.contributor.author.fl_str_mv |
Lucca,Fernando de Azevedo Malaguti,Carla Chebli,Liliana Andrade Reboredo,Maycon Moura Pinheiro,Bruno Valle Ribeiro,Tarsila Campanha da Rocha Azevedo,Felipe Meirelles de Corrêa,José Otávio do Amaral Gaburri,Pedro Duarte Chebli,Julio Maria Fonseca |
dc.subject.por.fl_str_mv |
Crohn disease Inflammatory Bowel Diseases Infliximab. Motor activity |
topic |
Crohn disease Inflammatory Bowel Diseases Infliximab. Motor activity |
description |
SUMMARY AIM: To compare the level of physical activity (PA), exercise capacity, and body composition before and after infliximab-induced clinical remission in patients with Crohn's disease (CD). METHODS: This prospective longitudinal study evaluated 44 adult outpatients with active CD before infliximab administration and 24 weeks after infliximab therapy. The patients were evaluated for PA in daily life, exercise capacity, muscle strength, and body composition. RESULTS: 38 (86.4%) patients achieved infliximab-induced remission at 24 weeks and presented an increment in the number of steps taken of 1092 (7440±2980 vs. 6348±3177, respectively; p=0.006). The inactive time was reduced when compared to the baseline value (454.2±106.3 vs. 427.9±97.8, respectively; p=0.033). There was no difference in the distance walked before and after infliximab therapy, while there was an increase in the fat mass index in responders to infliximab compared to the baseline (19.1±7.6 vs. 14.9±5.8; p=0.001). CONCLUSIONS: Infliximab-induced remission was shown to be effective for increasing physical activity by improving the number of steps and reducing inactive time. The maintenance of clinical remission associated with incentives to regular PA may contribute to making these patients reach an ideal level of PA. |
publishDate |
2020 |
dc.date.none.fl_str_mv |
2020-11-01 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0104-42302020001101566 |
url |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0104-42302020001101566 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
10.1590/1806-9282.66.11.1566 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
text/html |
dc.publisher.none.fl_str_mv |
Associação Médica Brasileira |
publisher.none.fl_str_mv |
Associação Médica Brasileira |
dc.source.none.fl_str_mv |
Revista da Associação Médica Brasileira v.66 n.11 2020 reponame:Revista da Associação Médica Brasileira (Online) instname:Associação Médica Brasileira (AMB) instacron:AMB |
instname_str |
Associação Médica Brasileira (AMB) |
instacron_str |
AMB |
institution |
AMB |
reponame_str |
Revista da Associação Médica Brasileira (Online) |
collection |
Revista da Associação Médica Brasileira (Online) |
repository.name.fl_str_mv |
Revista da Associação Médica Brasileira (Online) - Associação Médica Brasileira (AMB) |
repository.mail.fl_str_mv |
||ramb@amb.org.br |
_version_ |
1754212835573891072 |